MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

Medicines beginning with F

Flurbiprofen

Flurbiprofen 8.75mg lozenges

Incompatible

Stability notes for Flurbiprofen 8.75mg lozenges

Unsuitable due to administration.

Provenance

This compatibility recommendation is derived from Strefen Honey and Lemon 8.75mg lozenges (Reckitt Benckiser Healthcare (UK) Ltd).

Supplier

Strefen Honey and Lemon 8.75mg lozenges (Reckitt Benckiser Healthcare (UK) Ltd)

Flurbiprofen 8.75mg lozenges sugar free

No stability information

Stability notes for Flurbiprofen 8.75mg lozenges sugar free

There are no stability notes for this medicine.

Supplier

Strefen Orange 8.75mg lozenges sugar free (Reckitt Benckiser Healthcare (UK) Ltd)

Flurbiprofen 50mg tablets

No stability information

Stability notes for Flurbiprofen 50mg tablets

There are no stability notes for this medicine.

Suppliers

Flurbiprofen 50mg tablets (A A H Pharmaceuticals Ltd)
Flurbiprofen 50mg tablets (Alliance Healthcare (Distribution) Ltd)
Flurbiprofen 50mg tablets (Viatris UK Healthcare Ltd)

Flurbiprofen 100mg tablets

No stability information

Stability notes for Flurbiprofen 100mg tablets

There are no stability notes for this medicine.

Suppliers (4) of Flurbiprofen 100mg tablets
Flurbiprofen 100mg tablets (A A H Pharmaceuticals Ltd)
Flurbiprofen 100mg tablets (Alliance Healthcare (Distribution) Ltd)
Flurbiprofen 100mg tablets (Medihealth (Northern) Ltd)
Flurbiprofen 100mg tablets (Viatris UK Healthcare Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.